Clinical trials: Chronic Pulmonary Obstruction
Pulmonary Disease, Chronic Obstructive
Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease
This is a randomised study to be conducted in patients with severe to very severe Chronic Obstructive Pulmonary Disease (COPD) to establish whether there is a need for these patients to be continuously treated with an inhaled…
- Trial name
- NCT00975195
- Testing
- tiotropium inhalation, salmeterol xinafoate, fluticasone propionate
- Where
- 222 sites in Australia, Belgium and 21 more
- Volunteers
- 2,488 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)
- Trial name
- NCT00103922
- Testing
- cilomilast
- Where
- 115 sites in United States
- Volunteers
- 600 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Airway Disease
Clinical Study to Investigate Safety and Performance of NeuRx DPS in Patients Undergoing Bilateral Lung Transplantation
This study is a prospective, single-center feasibility study to acquire more knowledge regarding the NeuRx DPS and develop a routine in the optimal pacing of the diaphragm with this system during the weaning period from…
- Trial name
- NCT02411383
- Testing
- NeuRx Diaphragm Pacing System
- Where
- Belgium
- Volunteers
- 4 people
- Sponsor
- Synapse Biomedical
Pulmonary Disease, Chronic Obstructive
A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.
The primary objective of this study is to assess pharmacokinetics of tiotropium + olodaterol fixed-dose combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) delivered by the RESPIMAT inhaler after 3 weeks once daily treatment in Japanese…
- Trial name
- NCT01703845
- Testing
- Tiotropium (high dose) + Olodaterol, Tiotropium (low dose) + Olodaterol
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
This study will evaluate the efficacy and safety of QVA149 (110/50 μg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate FDC (50/500 µg b.i.d.) in patients with moderate to severe COPD
- Trial name
- NCT02603393
- Testing
- QVA149, Tiotropium, Salmeterol/fluticasone
- Where
- 167 sites in Argentina, Austria and 19 more
- Volunteers
- 1,053 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Advanced Immunological Approach in COPD Exacerbation
Chronic obstructive pulmonary disease (COPD) are characterized by frequent relapses, often resulting from common bacterial infections. Enhancing the immune response in these patients may decrease the frequency of these relapses.
- Trial name
- AIACE (NCT02417649)
- Testing
- Ismigen
- Where
- 13 sites in Italy
- Volunteers
- 288 people
- Sponsor
- Lallemand Pharma AG
COPD
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
The goal of this clinical trial is to compare the acute bronchodilator effect of the Ipratropium / Levosalbutamol 1.25 mg \& 0.5 mg / 2.5 mL fixed dose combination nebuliser solution or Levosalbutamol 1.25 mg / 3 mL nebuliser…
- Trial name
- NCT05890638
- Testing
- Ipratropium / Levosalbutamol Fixed Dose Combination, Ipratropium + Levosalbutamol Free Dose Combination
- Where
- Turkey (Türkiye)
- Volunteers
- 74 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)
This is a randomised, double-blind, parallel-group, multi-centre study evaluating 15 milligram (mg) twice daily/ Bi-daily (BID) of losmapimod versus placebo, in addition to standard of care (SoC).
- Trial name
- NCT02299375
- Testing
- Losmapimod tablets, Salbutamol MDI
- Where
- 36 sites in Argentina, Brazil and 6 more
- Volunteers
- 184 people
- Sponsor
- GlaxoSmithKline
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
This study is evaluating the effectiveness of a dose counter for an inhaler device used to deliver medication to people diagnosed with asthma or COPD.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
- Trial name
- NCT01302587
- Testing
- Albuterol
- Where
- 25 sites in United States
- Volunteers
- 306 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Obstructive Pulmonary Disease
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments.
- Trial name
- AERIFY-4 (NCT06208306)
- Testing
- Itepekimab (SAR440340)
- Where
- 223 sites in United States, Argentina and 30 more
- Volunteers
- 669 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease
Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)
This is a single cohort, prospective post approval study conducted on patients with COPD in Canada. The study will enroll patients that have not responded to their current treatment of tiotropium alone, or who are on the fixed…
- Trial name
- POWER (NCT02202616)
- Testing
- Glycopyrronium /Indacaterol maleate
- Where
- Canada
- Volunteers
- 401 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease
This project is the stage of dose escalation, is was divided into single and multiple dose clinical study, This is a multi-center, randomized, double-blind, placebo-controlled , study to the safety, tolerability and…
- Trial name
- NCT06711991
- Testing
- TQC3927 powder for inhalation
- Where
- 7 sites in China
- Volunteers
- 48 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
COPD Remote Patient Monitoring Through Connected Devices
This study is a device study that will use a double-arm. It will integrate the ANNE ONE platform which continuously tracks enrolled COPD patients' vital signs and symptoms over the course of the study and digitally shares that…
- Trial name
- NCT05271474
- Testing
- ANNE ONE Platform
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Innovation Hub Enterprises
Chronic Obstructive Pulmonary Disease, COPD
Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD
The aim of this clinical trial is to investigate the safety and tolerability of oral, once-daily EP395 administration in COPD patients for 12 weeks.
- Trial name
- NCT05572333
- Testing
- EP395
- Where
- 6 sites in Germany, United Kingdom
- Volunteers
- 61 people
- Sponsor
- EpiEndo Pharmaceuticals
Asthma, COPD
Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects
An analysis of the costs and outcomes associated with hospitalization and treatment of Levalbuterol versus Racemic Albuterol in subjects with Asthma and COPD.
- Trial name
- POLARIS (NCT00667797)
- Testing
- levalbuterol HCl, albuterol Sulfate
- Where
- 18 sites in United States
- Volunteers
- 486 people
- Sponsor
- Sumitomo Pharma America, Inc.
Pulmonary Disease, Chronic Obstructive
12 / 48 Week Pivotal PFT vs PBO in COPD I
This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00782210
- Testing
- Olodaterol (BI1744)
- Where
- 54 sites in United States, Australia and 4 more
- Volunteers
- 625 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and laboratory safety assessments.
- Trial name
- CERA (NCT00758459)
- Testing
- AZD1236
- Where
- 14 sites in Bulgaria, Finland and 3 more
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary objective of the study is to evaluate structural changes effected by AD9668 in the airways of adults with Chronic Obstructive Pulmonary Disease (COPD) by Multi-Slice Computed Tomography (MSCT)
- Trial name
- NCT01054170
- Testing
- AZD9668
- Where
- 9 sites in Canada, Denmark and 3 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
This is a Phase 2 study in patients with chronic obstructive pulmonary disease (COPD) to assess the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and safety of two dose levels of CSJ117 in comparison to placebo.
- Trial name
- NCT04882124
- Testing
- CSJ117
- Where
- 15 sites in United States, Australia and 4 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Observational Study to Evaluate Health Status of Chronic Obstructive Pulmonary Disease (COPD) Patients in Response to Real-life Treatments in Thailand
The purpose of this study is to evaluate health status of uncontrolled Chronic Obstructive Pulmonary Disease (COPD) patients in response to treatments in clinical practice.
- Trial name
- NCT01169727
- Where
- 20 sites in Thailand
- Volunteers
- 684 people
- Sponsor
- AstraZeneca